Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial

Michael E. Nassif,Mohammed Qintar,Sheryl L. Windsor,Rita Jermyn,David M. Shavelle,Fengming Tang,Sumant Lamba,Kunjan Bhatt,John E. Brush,Andrew B. Civitello,Robert Gordon,Orvar Jonsson,B. Lampert,Jamie M. Pelzel,Mikhail Kosiborod

Empagliflozin Effects on Pulmonary Artery Pressure in Patients with Heart Failure: Results from EMpagliflozin Evaluation By MeasuRing ImpAct on HemodynamiCs in PatiEnts with Heart Failure (EMBRACE-HF) Trial

2021

Michael E. Nassif
Mohammed Qintar
Sheryl L. Windsor
Rita Jermyn
David M. Shavelle
Fengming Tang
Sumant Lamba
Kunjan Bhatt
John E. Brush
Andrew B. Civitello
Robert Gordon
Orvar Jonsson
B. Lampert
Jamie M. Pelzel
Mikhail Kosiborod

Background: Sodium glucose cotransporter 2 inhibitors (SGLT2i) prevent heart failure (HF) hospitalizations in patients with Type 2 Diabetes (T2D), and improve outcomes in those with HF and reduced ...

Keywords:

Empagliflozin
Medicine
Internal medicine
Hemodynamics
Cardiology
in patient
Heart failure
Sodium/Glucose Cotransporter 2
Type 2 diabetes
Pulmonary artery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations